Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Blanchet

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Clinical Therapeutics|April 21, 2019
Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant RecipientsMarie Allard, Alicja Puszkiel, Filomena Conti, et al.
Clinical Therapeutics|June 6, 2006
Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trialMarie-Christine Djian, Benoit Blanchet, Florence Pesce, et al.
British Journal of Clinical Pharmacology|January 29, 2023
Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case reportAnthia Monribot, Olivier Huillard, Nihel Khoudour, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 27, 2015
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenibCamille Tlemsani, Olivier Huillard, Jennifer Arrondeau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 3, 2023
Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides During Rituximab Maintenance TherapyNihel Khoudour, Florence Delestre, Fabienne Jabot-Hanin, et al.
Expert Opinion on Drug Safety|April 4, 2014
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patientsOlivier Huillard, Emilie Boissier, Benoit Blanchet, et al.
Oncotarget|September 3, 2016
Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinibGaёlle Noé, Audrey Bellesoeur, Audrey Thomas-Schoemann, et al.
Cancers|June 5, 2019
Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with NivolumabGaëlle Noé, Audrey Bellesoeur, Lisa Golmard, et al.
Clinical Genitourinary Cancer|October 22, 2019
Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer PatientsMarie-Liesse Joulia, Edith Carton, Anne Jouinot, et al.
Expert Opinion on Investigational Drugs|January 21, 2015
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeuticsJennifer Arrondeau, Olivier Huillard, Camille Tlemsani, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Clinical Therapeutics|April 21, 2019
Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant RecipientsMarie Allard, Alicja Puszkiel, Filomena Conti, et al.
Clinical Therapeutics|June 6, 2006
Comparison of the time to extubation after use of remifentanil or sufentanil in combination with propofol as anesthesia in adults undergoing nonemergency intracranial surgery: a prospective, randomized, double-blind trialMarie-Christine Djian, Benoit Blanchet, Florence Pesce, et al.
British Journal of Clinical Pharmacology|January 29, 2023
Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case reportAnthia Monribot, Olivier Huillard, Nihel Khoudour, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 27, 2015
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenibCamille Tlemsani, Olivier Huillard, Jennifer Arrondeau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 3, 2023
Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides During Rituximab Maintenance TherapyNihel Khoudour, Florence Delestre, Fabienne Jabot-Hanin, et al.
Expert Opinion on Drug Safety|April 4, 2014
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patientsOlivier Huillard, Emilie Boissier, Benoit Blanchet, et al.
Oncotarget|September 3, 2016
Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinibGaёlle Noé, Audrey Bellesoeur, Audrey Thomas-Schoemann, et al.
Cancers|June 5, 2019
Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with NivolumabGaëlle Noé, Audrey Bellesoeur, Lisa Golmard, et al.
Clinical Genitourinary Cancer|October 22, 2019
Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer PatientsMarie-Liesse Joulia, Edith Carton, Anne Jouinot, et al.
Expert Opinion on Investigational Drugs|January 21, 2015
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeuticsJennifer Arrondeau, Olivier Huillard, Camille Tlemsani, et al.
Pageof 11